Over 1,000 cumulative hours of qualitative and quantitative data collection and analysis have been utilized to update Nice Insight’s Oral Solid Dose, OSD: Market Insight, CDMO Pricing and Competitor Benchmarking study.
In our first oral solid dose (OSD) report, we explore the manufacturing challenges, key technologies, and benchmark batch pricing for this common modality of therapeutics.
We provide examples of approved therapeutics manufactured with different methodologies.
We provide pricing information from a vast dataset of tablets and capsules.
We spoke with subject matter experts (SMEs) from contract development and manufacturing service providers and buyers of outsourced services.
For the first edition of Nice Insight’s Oral Solid Dose, OSD: Market Insight, CDMO Pricing and Competitor Benchmarking study we have focused on the enormous OSD market. The quantitative research that we performed is supplemented by direct interviews conducted with multiple SMEs with diverse roles in the sector to obtain qualitative perspectives on the dynamics of the space.
The content presented here reflects over 1,000 hours of dedicated research, interviews, analysis, and composition required to develop the 2025 pricing study.
A team comprising six Ph.D.-level experts collaborated with a group of 10+ SMEs within the OSD manufacturing and development sector to probe and better understand benchmarks, current challenges, and the future of the industry.
Our staff with over 80 years of industry experience worked for over four months to advise on big-picture trends shaping the industry and to unify the data into a holistic view.
Individual interviews were performed with SMEs representing leadership, manufacturing, innovators, and other operations at small and midsized CDMOs to discuss pricing for contract development and manufacturing services.